Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Neuropore Therapies has started Phase I clinical trials with NPT200-11, a new potential treatment for Parkinson’s disease (PD).
Subscribe to our email newsletter
Earlier in January, the company entered into a world-wide collaboration with UCB to develop and commercialize NPT200-11 in all indications.
So far, the company has secured $20.5m of the potential $460m in total milestones through its collaboration with UCB.
Neuropore CEO Dieter Meier said: "We are pleased to have advanced NPT200-11 to first dose in man, a significant milestone in the development of this novel drug candidate.
"The decision to progress into Phase 1 follows several years of highly promising pre-clinical research.
"We believe that NPT200-11 has the potential to become an important advancement in the treatment of Parkinson’s Disease and other synucleinopathies."
Over the last seven years, Neuropore has conducted extensive research to develop new therapeutic products aimed at slowing the progression of PD and related disorders.
NPT200-11 was developed as part of this effort, while other scientifically new approaches with preclinical stage drug-candidates are ongoing.
The company noted that by stabilizing conformations of alpha-synuclein that are then incapable of assembling into toxic pore-like oligomers in cell membranes, NPT200-11, blocks the pathological protein misfolding, aggregation and deposition that contribute to synaptic dysfunction and cell death in PD and related disorders.